Emmanuel Chamorey
Overview
Explore the profile of Emmanuel Chamorey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
1681
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clotaire L, Rubera I, Duranton C, Gal J, Chamorey E, Humeau H, et al.
Trials
. 2025 Jan;
26(1):30.
PMID: 39881395
Background: /aims. Pseudoxanthoma Elasticum (PXE, OMIM 264800) is an autosomal, recessive, metabolic disorder characterized by progressive ectopic calcification in the skin, the vasculature and Bruch's membrane. Variants in the ABCC6...
2.
Ben Dhia S, Chauviere D, Mitrea D, Schiappa R, Pace Loscos T, Chamorey E, et al.
Acta Oncol
. 2025 Jan;
64:120-128.
PMID: 39871514
Introduction: Organ preservation (OP) strategies are gaining interest in improving the quality of life in the management of rectal cancer, particularly for tumors located in the distal or middle rectum....
3.
Contu S, Schiappa R, Chateau Y, Chamorey E
Ther Adv Drug Saf
. 2025 Jan;
16():20420986241299567.
PMID: 39830586
Background: Reporting serious adverse events (SAEs) is crucial to reduce or avoid toxicities that can lead to major consequences for patient's health due to treatments tested in clinical trials. Its...
4.
Culie D, Schiappa R, Contu S, Seutin E, Pace-Loscos T, Poissonnet G, et al.
JCO Clin Cancer Inform
. 2024 Dec;
8:e2300263.
PMID: 39657101
Purpose: Thyroid nodules are common in the general population, and assessing their malignancy risk is the initial step in care. Surgical exploration remains the sole definitive option for indeterminate nodules....
5.
Daguenet E, Chamorey E, Jmour O, Pigne G, Yuen C, Gadea E, et al.
J Geriatr Oncol
. 2024 Nov;
16(1):102147.
PMID: 39521717
Introduction: Chronological and functional aging complicates care in older patients, and therapeutic decisions need to consider individual needs to minimise morbidity and mortality. Therapeutic decisions should be guided by a...
6.
Chamorey E, Gal J, Mograbi B, Milano G
Pharmaceuticals (Basel)
. 2024 Jul;
17(7).
PMID: 39065667
The conventional rules for anti-cancer drug development are no longer sufficient given the relatively limited number of patients available for therapeutic trials. It is thus a real challenge to better...
7.
Bontoux C, Hofman V, Chamorey E, Schiappa R, Lassalle S, Long-Mira E, et al.
Am J Surg Pathol
. 2024 Jul;
48(9):1072-1081.
PMID: 38980727
Emerging therapies for non-small cell lung cancer targeting c-Met overexpression have recently demonstrated promising results. However, the evaluation of c-Met expression can be challenging. We aimed to study the inter...
8.
Chamorey E, Pujalte-Martin M, Ferrero J, Mahammedi H, Gravis G, Roubaud G, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892246
This ABIGENE pharmacokinetic (PK) study sought mainly to characterize the unchanged drug PK during long-term abiraterone acetate (AA) administration in advanced prostate cancer patients (81 patients). It was observed that...
9.
Pace-Loscos T, Gal J, Contu S, Schiappa R, Chamorey E, Culie D
BMC Bioinformatics
. 2024 Jun;
25(1):210.
PMID: 38867185
Background: In the realm of biomedical research, the growing volume, diversity and quantity of data has escalated the demand for statistical analysis as it is indispensable for synthesizing, interpreting, and...
10.
Bailleux C, Gal J, Chamorey E, Mograbi B, Milano G
Pharmaceutics
. 2024 Feb;
16(2).
PMID: 38399265
Artificial intelligence (AI) is progressively spreading through the world of health, particularly in the field of oncology. AI offers new, exciting perspectives in drug development as toxicity and efficacy can...